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Abstract
Background: Hydrogen sulphide (H2S) is a gaseous neuro-mediator that exerts analgesic effects in rodent models of 
visceral pain by activating KATP channels. A body of evidence support the notion that KATP channels interact with 
endogenous opioids. Whether H2S-induced analgesia involves opioid receptors is unknown.
Methods: The perception of painful sensation induced by colorectal distension (CRD) in conscious rats was measured 
by assessing the abdominal withdrawal reflex. The contribution of opioid receptors to H2S-induced analgesia was 
investigated by administering rats with selective μ, κ and δ opioid receptor antagonists and antisenses. To investigate 
whether H2S causes μ opioid receptor (MOR) transactivation, the neuronal like cells SKNMCs were challenged with H2S 
in the presence of MOR agonist (DAMGO) or antagonist (CTAP). MOR activation and phosphorylation, its association to 
β arrestin and internalization were measured.
Results: H2S exerted a potent analgesic effects on CRD-induced pain. H2S-induced analgesia required the activation of 
the opioid system. By pharmacological and molecular analyses, a robust inhibition of H2S-induced analgesia was 
observed in response to central administration of CTAP and MOR antisense, while κ and δ receptors were less involved. 
H2S caused MOR transactivation and internalization in SKNMCs by a mechanism that required AKT phosphorylation. 
MOR transactivation was inhibited by LY294002, a PI3K inhibitor, and glibenclamide, a KATP channels blocker.
Conclusions: This study provides pharmacological and molecular evidence that antinociception exerted by H2S in a 
rodent model of visceral pain is modulated by the transactivation of MOR. This observation provides support for 
development of new pharmacological approaches to visceral pain.
Introduction
Visceral pain is the most common sign of acute and
chronic gastrointestinal, pelvic and genitourinary dis-
eases. As one of the most common causes of persistent
disability, visceral pain represents a frequent reason for
patients to seek medical treatment. Despite multiple
therapeutic approaches, the treatment of visceral pain
remains a significant challenge.
A complex network of signaling molecules mediates
perception of visceral pain [1]. Hydrogen sulphide (H2S)
is a gaseous neuromodulator generated from L-cysteine
by the activity of two pyrodoxal-5'-phosphate-dependent
enzymes, the cystathionine γ-lyase (CSE) and the cysta-
thionine β-synthase (CBS) [2-5], that exerts regulatory
activities in the gastrointestinal tract [1,4]. In the central
nervous system H2S mediates the induction of hippocam-
pal long-term potentiation [6-8] and the release of the
corticotropin releasing hormone from the hypothalamus
[9], enhances NMDA receptor-mediated responses [8]
and protects against peroxynitrite-induced neuronal tox-
icity [10]. ATP-sensitive potassium (KATP) channels have
been identified as important mediators of several effects
exerted by H2S [2,3,10]. Thus, glibenclamide, a KATP
channels blocker, attenuates analgesic effect of H2S in a
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model of visceral pain induced by colorectal distension
(CRD) in healthy and post-colitis, allodynic rats [11,12].
Opioid receptors are G protein-coupled receptors
(GPCRs) and the main receptors involved in the modula-
tion of pain in mammals [13,14]. The principal opioid
receptor subtypes, μ (MOR), δ (DOR) and κ (KOR), are
all expressed in the spinal cord and in the brain contribut-
ing to the modulation of nociceptive transmission. In
addition, the μ and κ opioid receptors are also expressed
in the enteric nervous system. MOR is the preferred
r e c e p t o r  f o r  p o t e n t  a n a l g e s i c s  w i t h  h i g h  p o t e n t i a l  f o r
abuse, such as morphine [14]. Endogenous opioids,
including enkephalins, endorphins and opiates like etor-
phine, induce rapid μ receptor endocytosis in neurons
and transfected cells [15,16], a process called internaliza-
tion that is widely used as a marker of MOR activation
[17,18].
Opioid receptors and KATP channels converge in regu-
lating release of neurotransmitters, smooth muscle con-
tractions and neuronal excitability with both signaling
pathways being effective in attenuating perception of vis-
ceral painful sensations in animal models and patients
[19,20]. Whether H2S signaling integrates with the opioid
system, however, is still unknown.
In the present study we provide evidence that antinoci-
ception exerted by H2S in a rodent model of visceral pain
is selectively modulated by the intervention of μ opioid
receptors. By in vitro studies we demonstrated that a pre-
viously unrecognized neuronal circuit with H2S-activated
KATP channels transactivating the μ opioid receptor sup-
ports the analgesic activities of H2S. These results iden-
tify new pharmacological targets in the treatment of
chronic visceral pain.
Results
H2S inhibits CRD-induced nociception
In all experimental settings two sequential distension-
effect curves were constructed. The first distension-effect
curve was used as a control, while the second was con-
structed in response to saline or specified drug. In all
experiments animals were awake and no changes in the
consciousness state were produced by Na2S administra-
tion.
CRD (0.4-1.6 ml water) elicited a volume-dependent
increase of the AWR scores which was rapid in onset,
persisted for the duration of the distension period (Figure
1, panel A) and returned to the baseline immediately after
the distension was stopped. In the fed animals CRD elic-
ited a similar pattern of response (Figure 1, panel B).
Injected intraperitoneally (i.p.) at the dose of 100 μMol/
kg, Na2S decreased the AWR score (Figure 1, panel C, p <
0.05 versus CRD alone) and determined a significant
increase of colorectal compliance (data not shown) indi-
cating that H2S induced a myorelaxant action on colonic
smooth muscle cells. The antinociceptive effect of Na2S
was confirmed by analysis of spinal cFos mRNA expres-
sion. Thus, Na2S administration abrogated cFos mRNA
expression induced in the spinal cord by CRD (Figure 1,
panel D, p < 0.05 versus control).
μ opioid receptors antagonism inhibits the H2S-induced 
antinociception
The antinociceptive effect of Na2S on CRD-induced pain
was studied by pre-treating animals with selective opioid
receptor antagonists. As illustrated in Figure 2, while the
DOR antagonist NTI, and the KOR antagonist GNTI
injected intracerebroventricularly (i.c.v.) had no effect on
Na2S-induced antinociception (Figure 2, panels A and B
respectively, p < 0.05 versus CRD), the selective MOR
antagonist CTAP injected i.c.v. reverted analgesia
induced by Na2S (Figure 2, panel C) without interfering
with its myorelaxant activity (data not shown). Adminis-
tering rats with NTI, GNTI and CTAP alone had no
effect on CRD-induced nociception (data not shown). To
confirm the above mentioned results by another method,
we injected rats i.c.v. with oligodeoxynucleotide anti-
senses directed against each specific opioid receptor sub-
type. While pre-treating rats with mismatched antisenses
f a i l e d  t o  m o d u l a t e  N a 2S-induced analgesia (Figure 3,
panel A, p < 0.05 versus CRD), the analgesic activity of
H2S on CRD-induced pain was abrogated by pre-treating
animals with δ and μ opioid receptor antisenses (Figures
3, panels B and D respectively). In contrast, no effect was
observed with the κ opioid receptor antisense (Figure 3,
panel C, p < 0.05 versus CRD). All antisenses had no
effect on colonic myorelaxation induced by Na2S (data
not shown). Finally, administering rats with antisenses
alone had no effect on nociception induced by CRD (data
not shown).
To determine whether the analgesic effect of Na2S was
modulated by KATP channels, we performed an experi-
ment by using the KATP channel antagonist glibenclamide.
The antinociceptive effect of Na2S (Figure 4, panel A) was
reverted by blocking the KATP  channels with glibencl-
amide (Figure 4, panel B), while treating rats with gliben-
clamide alone failed to modulate nociception induced by
CRD (data not shown).
H2S induces MOR activation and internalization
To investigate the mechanisms by which Na2S activates
MOR, experiments were carried out in SKNMC cells, a
neuron-like cell line that expresses functional μ opiod
receptors. Agonist-induced activation of MOR results in
conformational changes of the extracellular portion of the
receptor that unmasks a specific epitope near to the N-Distrutti et al. Molecular Pain 2010, 6:36
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terminus. By using a specific antibody that target this
epitope, we have investigated whether Na2S causes MOR
activation. As illustrated in Figure 5, panels A and B,
MOR activation was detected in cells exposed to either
the μ receptor-selective enkephalin analog DAMGO and
Na2S, indicating that exposure to Na2S induced an activ-
ity-dependent conformational change of the N-terminal
r e g i o n  o f  t h e  M O R.  F u r t h e r ,  e x p o s u r e  o f  S K N M C s  t o
Na2S caused the direct phosphorylation of MOR in the
Ser(377) (Figure 5, panel C), a measure of the receptor
activation, and exposure of cells to DAMGO also caused
a robust induction of MOR phosphorylation in the serine
residue, thought that the kinetic of the two effects was
different (Figure 5, panel C). As expression of total MOR
protein did not change (Figure 5, panel D), these results
demonstrated that exposure of SKNMCs to Na2S induced
a rapid and persistent phosphorylation of the μ opioid
receptor in a site that is functionally linked to its activa-
tion.
Following its activation, MOR is rapidly internalized
after its recruitment into a multiprotein complex with β
arrestin. By co-immunoprecipitation experiments (Figure
5 ,  p a n e l  E )  w e  f o u n d  t h a t  e x p o s u r e  o f  S K N M C s  t o
DAMGO and Na2S caused a robust induction of MOR
association with β arrestin. By membrane fraction tech-
nique we found that DAMGO caused MOR internaliza-
tion as shown by its disappearance from the plasma
membrane and relocation into the cytosol fraction as
early as 5 minutes of exposure (Figure 5, panel F). A simi-
lar pattern was observed in response to Na2S, thought the
Figure 1 Na2S induces antinociception. CRD induces a volume-dependent increase of the AWR score in both fasting and fed rats (panels A and B 
respectively) and Na2S (100 μMol/kg i.p.) causes a significant reduction of visceral sensitivity and pain (panel C). Data are mean ± SEM of 5 rats. *p < 
0.05 versus CRD. CRD induces the increase of spinal cFos expression that is downregulated by Na2S (panel D). Data are mean ± SEM of 5 rats. *p < 0.05 
versus control.
A C
2
3
4
R
 
s
c
o
r
e
2
3
4
*
R
 
s
c
o
r
e
0.0 0.4 0.8 1.2 1.6
0
1
2
Di t di l ( l)
A
W
R
0.0 0.4 0.8 1.2 1.6
0
1
*
*
*
Distending volume (ml)
A
W
CRD
Saline (10 l icv) + saline (10 l ip) + CRD
Distending volume (ml)
CRD
Saline (10 l icv) + Na2S (100Mol/kg ip) + CRD
Distending volume (ml)
3
A 4
D B
1
2
*
n
a
l
 
c
F
o
s
 
(
m
R
N
A
2
d
d
-
C
t
)
2
3
A
W
R
 
s
c
o
r
e
D
Control
CRD
H 2 S+CRD
0
S
p
i
n
0.0 0.4 0.8 1.2 1.6
0
1
CRD
Distending volume (ml)
A
Fed
H 2 CRD
Saline(10 l icv) + saline (10 l ip) +CRDDistrutti et al. Molecular Pain 2010, 6:36
http://www.molecularpain.com/content/6/1/36
Page 4 of 16
time course was slightly different (Figure 5, panel G).
These findings were confirmed by confocal microscopy
analysis (Figure 5, panels H-L). Thus, while resting SKN-
MCs exhibited MOR immunoreactivity predominantly at
the cell surface (Figure 5, panel H), a massive transloca-
tion of receptor to the cytosol occurred in cells exposed
to DAMGO (Figure 5, panel I) and Na2S (Figure 5, panel
L).
To further investigate whether activation of MOR by
Na2S occurs by direct receptor activation or is mediated
by receptor transactivation, we challenged SKNMCs with
the highly selective μ receptor antagonist CTAP. Results
from these experiments demonstrate that while MOR
activation induced by DAMGO was abrogated by CTAP,
the antagonist had no effects on MOR activation induced
by Na2S (Figure 6, panel A). Similarly, CTAP was effective
in preventing MOR internalization induced by DAMGO
but only partially prevented cytosolic MOR translocation
induced by Na2S treatment (Figure 6, panel B).
H2S induces PI3K/AKT activation
Because H2S induces AKT phosphorylation [21] and
AKT is also activated in response to MOR activation by
DAMGO [22], we have investigated whether Na2S
induces AKT phosphorylation in SKNMCs. Results of
these experiments demonstrated that both DAMGO and
Na2S caused a long-lasting phosphorylation of AKT in
Threonine 308 (Thre308), a marker of AKT activation
(Figure 7, panel A). The induction of AKT phosphoryla-
Figure 2 CTAP reverses the Na2S-induced antinociception. Pre-treating rats with the selective μ opioid receptor antagonist CTAP (0.09 mg/kg i.c.v. 
thirty minutes before Na2S; panel C) abrogates the antinociceptive effect of Na2S (100 μMol/kg i.p.). In contrast, the selective δ opioid receptor antag-
onist NTI (4 μg/kg i.c.v. five minutes before Na2S, panel A) and the selective κ opioid receptor antagonist GNTI (0.08 μmg/kg i.c.v. three days before 
Na2S, panel B) do not inhibit the analgesic effect of Na2S, indicating that δ and κ opioid receptors have no effects on Na2S-induced antinociception. 
Data are mean ± SEM of 5 rats. *p < 0.05 versus CRD.
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tion by Na2S was time dependent as further confirmed by
an immunoassay that specifically detects AKT phospho-
rylation on Serine 473 (Ser473) (Figure 7, panel B). AKT
phosphorylation induced by DAMGO was reversed by
CTAP (Figure 7C). However, CTAP failed to inhibit AKT
phosphorylation induced by Na2S (Figure 7, panel C and
D, p < 0.05 versus control).
To investigate the role of the PI3K/AKT pathway in
Na2S-induced MOR internalization, SKNMCs were pre-
treated with the selective PI3K inhibitor LY294002 (50
μM). LY294002 had no effect on DAMGO-induced MOR
internalization (Figure 8, panel A), but prevented MOR
internalization induced by Na2S (Figure 8, panel B).
Moreover, LY294002 abrogated AKT phosphorylation
induced by Na2S (Figure 8, panel C).
SKNMCs express KATP channels subunits: glibenclamide 
inhibits MOR activation and AKT phosphorylation
Because glibenclamide abrogates analgesia induced
by Na2S suggesting the involvement of KATP channels,
we have investigated whether SKNMCs express func-
tional KATP channels. By RT-PCR we found that both
the Kir6.2 and SUR1 subunits were expressed in the
SKNMCs (Figure 9, panels A and B respectively) and
by antagonism experiments we demonstrated that
these channels were functionally active because glib-
enclamide (1 μM) inhibited MOR activation (Figure 9,
panel C), MOR internalization (Figure 9, panel D) and
AKT phosphorylation (Figure 9, panel E) induced by
Na2S.
Figure 3 The selective antisense oligodeoxynucleotide probes against DOR and MOR reverse the Na2S-induced antinociception. Pre-treat-
ing rats with both the mismatched antisense oligodeoxynucleotides (panel A) and the κ opioid receptor antisense oligodeoxynucleotides (panel C) 
does not modify the H2S-induced decrease of the AWR score, confirming that KOR does not cause any change on the Na2S-induced analgesia. In con-
trast, oligodeoxynucleotide probes against DOR and MOR reverse the antinociception caused by Na2S (panel B and D respectively). Data are mean ± 
SEM of 5 rats. *p < 0.05 versus CRD.
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Discussion
In this study we have demonstrated that H2S induces μ
opioid-dependent analgesia in a rodent models of visceral
pain. Moreover, in a supplementary experiment, we have
demonstrated that, in contrast to what previously
reported on the effect of meal on visceral perception in
humans [23-25], CRD induces a similar painful response
in both fasting and fed animals, indicating that meal has
no influence on visceral perception in this experimental
setting. However, more experiments are needed to clarify
this particular issue.
Several mechanisms might explain the antinociceptive
effect of H2S. First, a bluntness of sensorial functions that
mimics a pain-free condition is unlikely because we did
not observe any change in the consciousness of the rats
during these studies. Second, as H2S causes a relaxation of
smooth muscle cells, H2S could simply act as myorelaxant
agent. However, this explanation seems unlikely, given
that we have previously demonstrated that H2S inhibited
CRD-induced nociception at doses that did not modify
the colorectal compliance [11]. A third, more likely expla-
nation would be that the antinociceptive effect of H2S is
m e d i a t e d  b y  a  d i r e c t  i n h i b i t o r y  a c t i v i t y  o n  c o l o r e c t a l
afferent pathways. Consistent with this view, we found
that administration of H2S decreased spinal cord expres-
sion of cFos mRNA.
The widespread occurrence of the opioid receptors
indicates that opioids have the potential for affecting
multiple systems, including nervous, hormonal and
immunological systems. Opioid receptors have specific
pharmacological profiles and physiological functions,
maintain a certain degree of selectivity for various opioid
ligands, and display unique patterns of expression in the
nervous system, even though there is overlap in their
binding affinity, distribution and function [26,27]. Ago-
nists of μ opioid receptors produce analgesia, affect mood
and rewarding behavior and alter respiratory, cardiovas-
cular, gastrointestinal and neuroendocrine functions [27].
While the actions of μ opioid agonists are invariably anal-
gesic, those of κ agonists can be either analgesic or anti-
analgesic, the last effect being mediated by a functional
antagonism on the action of μ receptor agonists. δ opioid
receptor agonists also are potent analgesics in animals
a n d ,  i n  i s o l a t e d  c a s e s ,  h a v e  p r o v e d  u s e f u l  i n  h u m a n
beings [27]. The main barrier to the clinical use of δ ago-
nists is that the most available agents are peptides that do
not cross the blood-brain barrier, thus requiring intraspi-
nal administration. The ability to elucidate the roles of
opioid receptor subtypes in the mediation of analgesia
was first enhanced by the development of selective opioid
receptor subtype antagonists direct against μ, κ and δ
receptors and subsequently by the use of antisense probes
to establish the relationship of the cloned receptors to
opioid actions using sequences complementary to
regions of specific exons of mRNA to down-regulate opi-
oid receptor proteins.
In the present study we described for the first time that
the analgesic effects of H2S is reverted by central opioid
antagonism. In particular, the selective μ antagonist
CTAP, centrally administered, inhibits the H2S-induced
Figure 4 Glibenclamide reverses the Na2S-induced antinociception. In a different experiment we have analyzed the role of the KATP channels on 
the H2S-induced analgesia (panel A). Pre-treating rats with the KATP channels selective blocker glibenclamide (2.8 μmol/kg i.v.) completely reverses the 
Na2S-induced analgesia (panel B) without any effects on the change of the colonic compliance induced by Na2S. Data are mean ± SEM of 5 rats. *p < 
0.05 versus CRD.
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analgesia while the selective κ and δ receptor antagonists
have no effect. Moreover, when the selective, centrally
administered antisense olygodeoxynucleotides have been
used, the antisense oligodeoxynucleotides direct against
μ receptors confirm the pharmacological data, suggesting
that the μ opioid receptors are primarily involved in the
mediation of H2S-induced analgesia. In contrast, our
pharmacological and antisense oligodeoxynucleotides
studies converge onto the indication that κ opioids recep-
tors do not alter the H2S-mediated effects on visceral sen-
sitivity and pain. Previous pharmacological data
indicating that activation of δ opioid receptors attenuates
responses to noxious stimuli [28-31] were confirmed by
studies conducted by using olygodeoxynucleotide probes
direct against δ opioids receptors [32-34]. In our study,
the selective δ opioid receptor antagonist NTI has no
Figure 5 Na2S induces MOR activation and phosphorylation, the recruitment of β arrestin and MOR internalization. Both DAMGO (1 μM) and 
Na2S (50 μM) induce MOR activation (panel A and B respectively). Treating SKNMCs with both DAMGO and Na2S results in MOR phosphorylation that 
is time-dependent. DAMGO induces MOR phosphorylation at Ser(377) that is maximal at 30 minutes and, similarly, H2S induces MOR phosphorylation 
that peaks at 3-6 minutes and persists until 30 minutes (panel C). The total DAMGO-induced and H2S-induced MOR phosphorylation is unchanged 
within the duration of the experiment (panel D). Co-immunoprecipitation experiments demonstrate that DAMGO induces the rapid complex be-
tween MOR and β arrestin with the peak at 5-15 minutes and, similarly, H2S induces the co-immunoprecipitation of MOR and β arrestin that peaked 
at 30 minutes (panel E), indicating that H2S induces the interaction between β arrestin and MOR. At the cell membrane fractioning experiments, DAM-
GO (1 μM) causes the disappearance of MOR from the plasma membrane fraction at 5 minutes and this effect is maximal at 60 minutes. At the same 
time there is a progressive increment of MOR presence in the cytoplasmatic fraction (panel F). After Na2S (50 μM), MOR disappears from the plasma 
membrane fraction at 30 minutes with the maximal effect at 60 minutes and, in contemporary, it passes into the cytoplasmatic fraction (panel G). At 
the confocal microscopy SKNMCs exhibit MOR immunoreactivity predominantly localized at the cell surface in nonstimulated condition (panel H) and 
it translocates to cytoplasm after activation with DAMGO (panel I), which is known to induce MOR internalization. Na2S induces a massive translocation 
of MOR from plasma membrane into the cytoplasm in most neurons (panel L). Data are representative of at least 3 experiments. *p < 0.05 vs control.
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effect on the H2S-induced analgesia, while the oligode-
oxynucleotide probes against DOR cause the reversion of
the analgesic effect exerted by H2S, suggesting a relatively
minor contribution of δ opioid receptors to pain modula-
tion by H2S. However, the discrepancy between pharma-
cological and antisense data about the modulation of
H2S-induced analgesia by δ opioid receptors needs to be
clarified by further studies.
Although hundreds of studies performed by using both
pharmacological approaches and antisense probes
focused on the different ability of the opioid receptors to
cause analgesia, our data fit with the notion that MOR is
identified as the most important opioid receptor linked
with pain system so that the selective μ endogenous or
exogenous agonists are invariably analgesic while selec-
tive μ opioid antagonists induce or exacerbate pain by
blocking the effects of μ agonists in several experimental
conditions. Because antisenses are highly selective and
specific in downregulating one opioid receptor without
interfering with the activity of other subtypes [35], these
pharmacological and antisense studies converge in the
indication that μ opioid receptors mediate H2S-induced
analgesia.
In the present study we have provided evidence that the
analgesic activity of H2S is mediated by the recruitment
of μ opioid receptor. In addition to specific pharmacolog-
ical antagonism exerted in vivo by CTAP and MOR anti-
sense on antinociceptive activity of H2S, results from in
vitro  pharmacological dissection of signaling pathways
activated by H2S are consistent in supporting the view
that H2S transactivates the μ opioid receptor. Exposure of
SKNMCs to H2S causes conformational changes of the
extracellular tail of MOR that are known to be associated
with an activated state of the receptor. These conforma-
tional changes of the N-terminus unmasks a specific
epitope that can be detected by an activation-state spe-
cific antibody [36,37]. Results of experiments carried out
using this approach have revealed that exposure of SKN-
MCs to H2S causes a change in the conformational status
of MOR similar to that induced by the enkephalin analog
DAMGO, a potent agonist of MOR. Further, and simi-
larly to DAMGO, H2S causes a robust, time- and concen-
tration-dependent phosphorylation of MOR in Ser(377),
a site that is specifically required to induce receptor acti-
vation and internalization by DAMGO. Previous studies
have shown that among the 12° potential phosphorylation
Figure 6 CTAP only partially inhibits the Na2S-induced MOR internalization. SKNMCs are stimulated with DAMGO (1 μM) or Na2S (50 μM) in pres-
ence or in absence of CTAP (1 μM) and the effects on MOR activation and internalization are detected. CTAP inhibits the MOR activation induced by 
DAMGO while it has no effect on that induced by Na2S (panel A). CTAP blocks the DAMGO-induced MOR internalization but, in contrast, it only partially 
inhibits the Na2S-induced MOR internalization (panel B). Data are representative of at least 3 experiments. *p < 0.05 vs control, **p < 0.05 vs DAMGO 
alone.
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sites present in the C-tail of MOR, only Ser(363),
Thre(370) and Ser(375) are involved in MOR phosphory-
lation and linked to receptor activation [38]. DAMGO-
induced MOR phosphorylation occurs at Thre (370) and
Ser(375) [Ser(377) in human receptor] but only mutation
of Ser(375) is reported to attenuate the rate and extent of
receptor internalization [38].
One important observation we made is that phospho-
rylation of MOR's Ser(377) induced by H2S is rapidly
reversible. Because prolonged activation of μ opioid
receptors leads to their phosphorylation, internalization,
desensitization and down-regulation and represents one
the main biochemical substrates of morphine tolerance,
the fact that H2S causes a short-lasting receptor phospho-
rylation and that rapid receptor phosphorylation (min)
does not directly correlate with the relatively slow rate of
desensitization (h) of MOR induced by morphine [27],
suggests that this mediator is unlikely to play a role in
long term desensitization of MOR and could still be a
pharmacological target in situation of MOR desensitiza-
tion
Mutational analysis has demonstrated that phosphory-
lation of Ser (375) or Ser(377) in the human receptor is
critical for DAMGO-induced MOR internalization [38].
In the present study we have shown that exposure of
SKNMCs to H2S not only results in Ser(377) phosphory-
lation but also in MOR internalization. Similarly to
DAMGO, H2S induces a loss of cell surface expression of
MOR as monitored by confocal microscopy and cell
membrane fractioning technique. MOR internalization
induced by H2S is mediated by its recruitment to a pro-
tein-protein complex with β arrestin [18]. Previous stud-
ies have shown that once phosphoryled, the opioid
receptor binds to β arrestin and is trafficked to clathrin-
coated pits where it can subsequently be internalized into
endosomes. Once internalized, endosomes containing
receptors can be fused with lysosomes where receptors
are proteolytically degraded or, alternatively, the recep-
tors are dephosphoryled, resensitized and recycled back
to membrane [39]. One of the main findings of the pres-
ent study is that H2S reproduces the same effects of
DAMGO in terms of MOR phosphorylation, association
Figure 7 Na2S induces AKT phosphorylation. Exposure to both DAMGO (1 μM) and Na2S (50 μM) causes AKT phosphorylation on Threonine 308 
as detected by Western blot analysis (panel A). Moreover, Na2S induces AKT phosphorylation on Ser(473) as detected by phospho AKT assay (panel 
B). CTAP inhibits the DAMGO-induced AKT phosphorylation on Thre(308) (panel C), while it does not prevent that induced by Na2S on Thre(308) and 
Ser(473) (panels C and D). Data are representative of at least 3 experiments. Data on AKT phosphorylation are mean ± SE of 5 experiments. *p < 0.05 
vs control.
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with β arrestin and internalization. However, H2S induces
a slower β arrestin recruitment and MOR internalization
than DAMGO, providing evidence that it does not
behave as a direct MOR agonist.
Results form mechanistic studies aimed at dissecting
intracellular signals activated by H2S in SKNMCs have
shown that H2S activates the PI3K/AKT pathway and
induces AKT phosphorylation [21]. PI3K is a lipid kinase
acting as a membrane-embedded second messenger [40]
and AKT is a downstream target of the PI3K [41]. Activa-
tion of MOR by DAMGO induces AKT phosphorylation
[42]. Our study confirms these observations and extend
this effect to H2S. However, while CTAP reverses AKT
phosphorylation induced by DAMGO, it fails to inhibit
the effects exerted by H2S on AKT, indicating that,
despite MOR trans-activation, H2S-induced AKT phos-
p h o ry l a t i o n  is  d u e  t o  a  d i r ect  e ff ect  o f  t h e  g as  o n  t h e
P I 3 K / A K T  p a t h w a y .  T h e  f a c t  t h a t  i n h i b i t i o n  o f  A K T
phosphorylation by the PI3K inhibitor LY294002 pre-
vents MOR internalization induced by H2S but not by
DAMGO, indicates that H2S directly activates the PI3K/
AKT pathway and that activation of this pathway is hier-
archically higher in the mechanism that leads to MOR
activation by H2S. These findings are consistent with the
observation that activation and internalization of a GPCR
can be regulated by activation of the PI3K/AKT pathway
[43].
The mechanism through which H2S targets the PI3K/
AKT pathway involves KATP  channels. Thus not only
SKNMCs express SUR1 and Kir6.2, but blocking these
channels with glibenclamide abrogates AKT phosphory-
lation and MOR activation and internalization induced
by H2S. This suggest a hierarchic order in the observed
effects with H2S acting as a KATP channels opener leading
to activation of PI3K/AKT pathway and MOR activation
and phosphorylation (Figure 10). Similar transactivation
Figure 8 LY294002 inhibits the Na2S-induced MOR internalization and AKT phosphorylation. The selective PI3K inhibitor LY294002 has no ef-
fects on DAMGO-induced MOR internalization (panel A), while it blocks that induced by Na2S (panel B). Furthermore, LY294002 inhibits the AKT phos-
phorylation induced by Na2S on Ser(473) (panel C). Data are representative of at least 3 experiments. Data on AKT phosphorylation are mean ± SE of 
5 experiments. *p < 0.05 vs control.
Y
2
9
4
0
0
2
Y
2
9
4
0
0
2
C
o
n
t
r
o
l
D
A
M
G
O
L
Y
2
9
4
0
0
2
D
A
M
G
O
+
L
Y
C
o
n
t
r
o
l
D
A
M
G
O
L
Y
2
9
4
0
0
2
D
A
M
G
O
+
L
Y
M
a
r
k
e
r
A
25 * C
Plasma membrane Cytoplasm
10
15
20
*
h
o
s
p
h
o
r
y
l
a
t
i
o
n
e
r
i
n
e
 
4
7
3

g
 
o
f
 
p
r
o
t
e
i
n
) C
0
2
0
2
Control Na2S
0
5
10
LY294002
A
K
T
 
p
h
S
e
(
m
U
/

B
o
n
t
r
o
l
a
2
S
a
2
S
+
L
Y
2
9
4
0
0
o
n
t
r
o
l
a
2
S
a
2
S
+
L
Y
2
9
4
0
0
a
r
k
e
r
Alone       +Na2S
C
o
N
a
N
a
C
o
N
a
N
a
M
a
Plasma membrane CytoplasmDistrutti et al. Molecular Pain 2010, 6:36
http://www.molecularpain.com/content/6/1/36
Page 11 of 16
of opioid receptors by epidermal growth factor receptor
has been recently described [44], however this is the first
evidence of transactivation of MOR by activation of KATP
channels.
Conclusion
This study demonstrates that, in a rodent model of vis-
ceral pain, H2S-induced analgesia is mediated by μ opi-
oids receptor activation as, in vivo, the selective
antagonism of MOR by i.c.v. administration of both
CTAP and antisenses direct against MOR reverses the
analgesic effects of H2S. Moreover, pre-treating rats with
the KATP  channels selective blocker glibenclamide
reverses the H2S-induced analgesia. The in vitro studies
performed comparing the effect of the μ receptor-selec-
tive enkephalin analog DAMGO and H2S confirm these
data demonstrating that, in the neuronal-cell line
SKNMC, both DAMGO and H2S induce MOR activation
and phosphorylation leading to interaction between
MOR and β arrestin and MOR internalization. CTAP
completely blocks MOR internalization induced by
DAMGO while, in contrast, it partially inhibits MOR
internalization induced by hydrogen sulphide. In addi-
t i o n ,  e x p o s u r e  t o  h y d r o g e n  s u l p h i d e  c a u s e s  t h e  P I 3 K /
AKT pathway activation and induces AKT phosphoryla-
tion. The selective PI3K inhibitor LY294002 does not
interfere with the DAMGO-induced MOR internaliza-
tion, while it causes the inhibition of the translocation
Figure 9 Glibenclamide inhibits Na2S-induced MOR activation and internalization and AKT phosphorylation. Qualitative PCR (panel A) and 
Quantitative Real-Time PCR (panel B) showing the expression of Kir6.2 and SUR1 in HepG2 (positive control) demonstrate that SKNMCs express both 
the KATP channels subunits Kir6.2 and SUR1. SKNMCs are stimulated with Na2S (50 μM) in presence or in absence of glibenclamide (1 μM) for 60 min-
utes. Glibenclamide prevents the Na2S-induced MOR activation (panel C) and internalization (panel D), while it has no effect on MOR internalization 
induced by DAMGO (panel D). Finally, glibenclamide inhibits AKT phosphorylation induced by Na2S, as assessed by phospho-immunoassay (panel F). 
Data are representative of at least 3 experiments. Data on AKT phosphorylation are mean ± SE of 5 experiments. *p < 0.05 vs control; **p < 0.05 vs 
DAMGO or Na2S alone.
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process of MOR from the plasma membrane to the cyto-
plasm induced by hydrogen sulphide as well as AKT
phosphorylation induced by hydrogen sulphide. As glib-
enclamide reverted the analgesia induced by hydrogen
sulphide, we hypothize that the ATP potassium channels
could modulate MOR activation induced by hydrogen
sulphide. First we have demonstrated that SKNMCs
express the ATP potassium channels subunits Kir6.2 and
SUR1. Moreover, glibenclamide inhibits both MOR and
AKT phosphorylation induced by hydrogen sulphide,
demonstrating that activation of ATP potassium channels
by hydrogen sulphide is a key process of these effects. On
these basis we can speculate that hydrogen sulphide acts
on the ATP potassium channels that induce the PI3K/
AKT pathway that, on turn causes MOR activation and
internalization (Figure 10). This study provides the first
evidence for a cross-talk between H2S and the μ opioid
receptors and paves the way to development of new ther-
apeutic approaches to visceral pain.
Methods
Materials
Sodium sulphide (Na2S) was used as donor of hydrogen
sulphide and was from Sigma-Aldrich (S. Louis, MO,
USA). Methylene blue, glibenclamide, naltrindole (NTI)
5'-guanidinonaltrindole (GNTI),D-Phe-Cys-Tyr-D-Trp-
Arg-Thr-Pen-Thr-NH2 (CTAP), mismatched and specific
antisense olygodeoxynucleotide probes for opioid recep-
tors, [D-Ala  2,N-Me-Phe  4,Gly  5-o1]enkephalin
(DAMGO), ascorbic acid, salicylic acid, potassium
hydroxide, trichloroacetic acid, pyridoxal-5'-phosphate
Figure 10 Schematic representation of H2S and opioid receptor interaction. The selective μ opioid receptor enkephalin analog DAMGO acts as 
a direct agonist of MOR leading to its activation, phosphorylation on Ser(377), co-immunoprecipitation with β arrestin and internalization (panel A and 
B). The selective MOR antagonist CTAP blocks the effects induced by DAMGO, while it only partially inhibits those induces by H2S. In contrast, H2S 
opens the KATP channels that activate the PI3K/AKT pathway leading to MOR activation, phosphorylation, co-immunoprecipitation with β arrestin and 
internalization, as the selective KATP channels blocker glibenclamide and the selective PI3K inhibitor LY294002 inhibit these effects (panel C and D).
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and calmodulin were from Sigma-Aldrich (S. Louis, MO,
USA). Tissue Protein Extraction Reagent (T-PER) was
obtained by Pierce Biotechnology (Rockford, IL, USA).
In vivo experiments
Animals
Male, Wistar rats (200-250 g, Charles River, Monza, Italy)
were housed in plastic cages and maintained under con-
trolled conditions with 12-hour light/dark cycles (lights
on at 07.00). Tap water and standard laboratory chow
were freely available (Additional file 1). It has been dem-
onstrated that the nutrients induce an enhancement of
the colorectal sensitivity in both healthy subjects [23] and
IBS patients [24,25]. To avoid the influence of the meal on
colorectal perception and pain, food was withdrawn 12
hours before surgical procedures and CRD recordings in
all  in vivo experiments [11,12]. However, to verify
whether meal could influence the perception of CRD-
induced visceral pain, we performed a supplementary
experiment on fed rats (n = 5). Experimental procedures
were approved by our institutional animal research com-
mittees and were in accordance with nationally approved
guidelines for the treatment of laboratory animals.
Surgical procedure
Rat were anesthetized by an i.p. injection of 70 mg/kg
penthotal and were then mounted in a stereotaxic instru-
ment. To perform the i.c.v. injection, a guide cannula
(Alzet Brain Infusion Kit II, 3-5 mm) was inserted stereo-
taxically into the right lateral cerebral ventricle. The ste-
reotaxic coordinates were 1,6 mm right laterally and 0,8
mm dorsoventrally from the bregma and 3,5 mm below
the dura. Drugs dissolved in 10 μl saline were injected
into the cerebral ventricle by insertion of an injection
cannula (28 gauge stainless steel tube) connected to a
catheter tube into the guide cannula which was con-
nected to a syringe. In each injection 10 μl of vehicle or
drugs were delivered manually into the ventricle over 3
min. At the end of each experiment, methylene blue solu-
tion was injected through the injection cannula to verify
its correct placement in the right lateral ventricle. Rats
exhibiting motor deficits after the surgical procedure
were not used in the subsequent experiments.
CRD and behavioral testing
All experiments began 1 week after the surgical proce-
dure. Distending procedure were performed as previously
described (Additional file 2). The behavioral response to
CRD was assessed by measuring the abdominal with-
drawal reflex (AWR) as previously described [45,46]
(Additional file 2).
Effects of H2S on colonic nociception
The control group (n = 5) consisted of fasting rats that
underwent surgical procedures but not CRD, while the
CRD group consisted of fasting rats that underwent sur-
gical procedures and two sets of CRD, the first acting as
control. To investigate whether H2S administration mod-
ulates sensitivity and pain induced by CRD, rats were
treated i.p. with vehicle (CRD group) or Na2S, an H2S
donor, at the dose of 100 μMol/kg five minutes before
CRD.
Effects of the opioid and KATP channels inhibitors
The role of the δ, κ and μ opioid receptors in the H2S-
induced antinociception was investigated by pre-treating
rats with selective opioid receptor antagonists adminis-
tered at final volume of 10 μl i.c.v.: NTI, a δ opioid recep-
tor antagonist (4 μg/kg), was injected 5 minutes before
Na2S [47]; GNTI, a κ opioid receptor antagonist (0.08
mg/kg), was administered three days before Na2S [48];
CTAP, a μ opioid receptor antagonist (0.09 mg/kg), was
administered 30 minutes before Na2S [49]. Control
experiments were performed by injecting rats with NTI,
GNTI and CTAP alone (n = 5 rats/group).
For antisense experiments rats were pretreated with
antisense oligodeoxynucleotides direct against specific
Table 1: Primer used for antisense experiments
Probe sequence Probe sequence
DOR-1 opioid receptor clone
Exon 1 AS TGT CCG TCT CCA CCG TGC
Exon 2 AS ATC AAG TAC TTG GCG CTC TG
Exon 3 AS AAC ACG CAG ATC TTG GTC AC
KOR-1 opioid receptor clone
Exon 1 AS GCT GCT GAT CCT CTG AGC CCA
Exon 2 AS CCA AAG CAT CTG CCA AAG CCA
Exon 3 AS GGC GCA GGA TCA TCA GGG TGT
MOR-1 opioid receptor clone
Exon 1 AS CGC CCC AGC CTC TTC CTC T
Exon 2 AS TTG GTG GCA GTC TTC ATT TTG G
Exon 3 AS TGA GCA GGT TCT CCC AGT ACC A
Exon 4 AS GGG CAA TGG AGC AGT TTC TG
Mismatch CGC CCC GAC CTC TTC CCT TDistrutti et al. Molecular Pain 2010, 6:36
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exons of DOR, KOR and MOR. A mismatched antisense
was used as control (Table 1). All antisense olygodeoxy-
nucleotides were administered i.c.v. in dose of 10 μg in 10
μl volume saline [50,52,53]. Treatment with antisenses
was performed on day 1, 3 and 5 and the behavioral test
was performed at day 6 [51] (Additional file 3).
The involvement of KATP channels in the analgesic
effects of H2S was assessed by pre-treating rats with glib-
enclamide, a selective KATP channel blocker, at a dose of
2.8 μmol/kg injected intravenously (i.v.) for 20 minutes
before Na2S administration [11,12] (Additional file 4).
At the end of the CRD procedures, rats were sacrificed
and spinal cords (L1-L5) collected for RT-PCR analysis of
cFOS [54] (additional file 5) using the following sense and
antisense primers: gtctggttccttctatgcag and taggtagtg-
cagctgggagt.
In vitro experiments
The immortalized human neuronal SKNMCs were used
for in vitro studies. Cells were grown in Minimum Essen-
t i a l  M e d i u m  w i t h  E a r l ' s  s a l t s  s u p p l e m e n t e d  w i t h  1 0 %
FBS, L-glutamine, penicillin and streptomycin, and regu-
larly passaged to maintain exponential growth.
For in vitro studies DAMGO was used at the dose of 1
μM and Na2S at the dose of 50 μM. To determine whether
H2S induces MOR activation, SKNMCs were stimulated
with DAMGO or Na2S and MOR activation detected by
Western blot analysis using a specific antibody raised
against a specific epitope in the N-terminus of the recep-
tor that becomes exposed in response to conformational
changes induced by receptor activation [55]. This activa-
tion-state specific antibody exhibits enhanced recogni-
tion of activated receptor [36,37]. In addition, activation
of MOR by H2S was detected by Western blot analysis of
receptor phosphorylation on Serine (Ser) (377). Finally,
because MOR activation results in receptor recruitment
to β arrestin, co-immunoprecipitation experiments were
performed to investigate whether H2S induces the forma-
tion of a protein-protein complex between MOR and β
arrestin (Additional file 6).
Effect of H2S on MOR internalization
T o  i n v e s t i g a t e  w h e t h e r  e x p o s u r e  o f  S K N M C s  t o  H 2S
induces MOR internalization, cells were treated with the
μ receptor-selective enkephalin analog DAMGO [15,16]
and Na2S alone or in combination with the MOR antago-
nist CTAP. Internalization of the receptor was assessed by
Western blot analysis by measuring its translocation from
the cell membrane fraction to the cytosol and by confocal
microscopy (Nikon) using a specific anti-MOR immuno-
fluorescent antibody (Additional file 7).
Effect of H2S on AKT phosphorylation
SKNMCs were exposed to DAMGO and Na2S up to 60
minutes and Western blot analysis performed on whole
cell lysates using a specific antibody that detected the
phosphorylated form of AKT on Thre(308). AKT phos-
phorylation was also detected by measuring the AKT
phosphorylated form on Ser(473) (phospho-AKT ELISA
KIT, Biosource).
Activation of the PI3K/AKT pathway was tested by
exposing SKNMCs to the selective PI3K inhibitor
LY294002 (50 μM) in the presence of DAMGO or Na2S
(Additional file 8).
Effect of KATP channels blockade
Expression of KATP channels in SKNMCs was evaluated
by assessing the expression of Kir6.2 and SUR1 sub-units
(Additional file 9). Qualitative and quantitative PCR were
performed by using the following sense and antisense
primers: hGAPDH: gaaggtgaaggtcggagt and catgggtg-
gaatcatattggaa; hSUR.1: gtccagatcatgggaggcta and cagaa-
gacagcccctgagac; hKir6.2: gtcaccagcatccactcctt and
ggggacttcaaatgttgcat. The effects of glibenclamide (1 μM)
on AKT phosphorylation and MOR activation and inter-
nalization were determined (Additional file 9).
Densitometric analysis
All the densitometric analysis have been performed by
using the Image J software.
Statistical analysis
Behavioral data are presented as mean ± SE, with sample
sizes of at least 5 rats per group. Statistical comparisons
of unpaired data were performed by the Mann-Whitney
test, while statistical comparisons of paired data were
performed by the Wilcoxon signed rank test. Densito-
metric data have been analyzed with T urkey's multiple
comparison test. Data on AKT phosphorylation are pre-
sented as mean ± SE, with sample sizes of at least 5 exper-
iments per group. An associated probability (p value) of
less that 5% was considered significant.
Additional material
Additional file 1 Animals. This file describes the animals used.
Additional file 2 CRD and behavioral testing. This file describes the 
behavioral testing used in the in vivo studies.
Additional file 3 Effects of the opioid receptors antagonism. This file 
describes the methods used for blocking the opioid receptors.
Additional file 4 Effects of KATP channels. This file describes the method 
used for blocking the KATP channels.
Additional file 5 Spinal cFOS expression. This file describes the method 
used for determining spinal cFos expression.
Additional file 6 Effect of H2S on MOR. This file describes the methods 
used to determine MOR activation
Additional file 7 Effect of H2S on MOR internalization. This file 
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